In line with this, an inhibitor of MEK, which suppresses MAPK-PI3K-mTOR pathways activity, has been shown to improve the anti-tumor effects of CD8+ T cells and benefit immune checkpoint blockade (ICB) therapy (38–41). Here, CD8A is linked to neoplasm.